Topic: hematologic cancer
This year’s ASH saw multiple presentations on BCMA-targeting drugs, but Jefferies says Bluebird’s CAR-T bb2121 “is still leading the pack.”
Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Aptose is now racing to resume dosing blood cancer patients with the c-Myc inhibitor in the paused phase 1b study.
Biotech IPOs continue to come thick and fast this week, with CAR-T specialist Autolus the latest to list with an impressive $150 million raise.
U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials.
Phase 3 results with Daiichi Sankyo's new FLT3 inhibitor quizartinib put it on course for regulatory filings in acute myeloid leukemia.
The partnership for Aptose's third drug candidate comes as the biotech looks set to have its two lead drugs in clinical testing in the coming months.
Medigene has been given a green light in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.
Bluebird Bio and Celgene’s CAR-T therapy bb2121 has pushed multiple myeloma into remission in more than half of the diseased patients treated.
Shares in Agios have fallen after a preview of ASH data that will be used to support an FDA filing for refractory acute myeloid leukemia candidate ivosidenib.